Using PRP injections to treat shoulder osteoarthritis
Outcomes Following Single Injections of Low-dose Platelet-rich Plasma (PRP), High-dose PRP, or Saline in Patients With Glenohumeral OA: a Randomized Controlled Trial
This study is testing whether different doses of PRP injections can help people with painful shoulder osteoarthritis feel better after other treatments haven't worked.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 135 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Hospital for Special Surgery, New York Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT05675527 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of platelet-rich plasma (PRP) injections in treating glenohumeral osteoarthritis by comparing low-dose and high-dose PRP preparations against a saline control. Participants aged 18-100 with significant shoulder pain due to osteoarthritis will receive one of the three treatments after failing conservative therapies. The study aims to determine which PRP dosage provides better outcomes for patients suffering from this condition. MRI confirmation of joint issues and a history of pain are required for eligibility.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-100 with moderate to severe shoulder pain due to glenohumeral osteoarthritis who have not responded to conservative treatments.
Not a fit: Patients with a history of prior PRP injections or recent steroid treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a more effective pain relief option for patients with shoulder osteoarthritis.
How similar studies have performed: Previous studies have shown some efficacy of PRP in treating glenohumeral osteoarthritis, but this study's comparison of different PRP dosages is a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18-100 years old * Average NRS pain greater than or equal to 5/10 as a direct result of glenohumeral osteoarthritis (any severity: mild, moderate, or severe) and/or chondral lesion or loss * At least 3 months of pain after onset of symptoms that has failed conservative treatments, including physical therapy * MRI of the affected joint * Transient relief of symptoms after a diagnostic intra-articular injection into the joint * Email address or network access Exclusion Criteria: * Inability to hold non-steroidal anti-inflammatory drugs for 2 weeks prior and 1 month after the injection * Prior platelet-rich plasma injection * Steroid injection within 3 months of the initial injection * Hyaluronic acid within 6 months of the initial injection * Involved in workers' compensation or active litigation involving the affected joint * History of Plavix use * Known uncontrolled systemic illness (uncontrolled diabetes, HIV, vasculitis, autoimmune/autoinflammatory disease) * Presence of acute fractures or gross mechanical deformities * Concurrent "uncontrolled" cervical disorders
Where this trial is running
New York, New York
- Hospital for Special Surgery — New York, New York, United States (Recruiting)
Study contacts
- Study coordinator: Jonathan Kirschner, MD
- Email: kirschnerj@hss.edu
- Phone: 646-714-6327
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.